Literature DB >> 19746221

A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report.

Se Hyun Kim1, Hyun Cheol Chung, Jaeheon Jeong, Ji Hoon Kim, Sun Young Rha, Joong Bae Ahn, Nam Hoon Cho, Hei-Cheul Jeung.   

Abstract

Atypical medullary carcinomas and carcinosarcoma have unique histopathological features. Here we present a case with a breast malignancy that had pathological characteristics of both. A 54-year old patient with a malignant breast mass received 6 cycles of adriamycin-based chemotherapy, followed by 3 cycles of paclitaxel monotherapy, and had a poor clinical response to treatment. A modified radical mastectomy was performed. The pathological diagnosis was complicated by an inability to distinguish between atypical medullary carcinoma and carcinosarcoma. The findings included a tumor that was well-circumscribed, high grade and a syncytial growth pattern as well as biphasic sarcomatous and carcinomatous characteristics. In conclusion, atypical medullary carcinoma and carcinosarcoma of the breast have entirely different prognoses and should be managed differently. Both should be treated by surgical resection, and additional therapy should be considered based on the cancer with the poorer prognosis.

Entities:  

Keywords:  Atypical medullary carcinoma; Carcinosarcoma; Metaplastic breast cancer; Neoadjuvant chemotherapy

Year:  2007        PMID: 19746221      PMCID: PMC2739326          DOI: 10.4143/crt.2007.39.3.134

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  12 in total

1.  Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up.

Authors:  R L Ridolfi; P P Rosen; A Port; D Kinne; V Miké
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

2.  Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT).

Authors:  Ha Vu-Nishino; Fattaneh A Tavassoli; Willam A Ahrens; Bruce G Haffty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

3.  Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.

Authors:  W Domagala; L Woźniak; J Lasota; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

Review 4.  Triple-negative breast cancer: therapeutic options.

Authors:  Susan Cleator; Wolfgang Heller; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

5.  Metaplastic breast cancer: prognosis and response to systemic therapy.

Authors:  D Rayson; A A Adjei; V J Suman; L E Wold; J N Ingle
Journal:  Ann Oncol       Date:  1999-04       Impact factor: 32.976

6.  Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast.

Authors:  H Gutman; R E Pollock; N A Janjan; D A Johnston
Journal:  J Am Coll Surg       Date:  1995-02       Impact factor: 6.113

7.  Biphasic metaplastic sarcomatoid carcinoma of the breast.

Authors:  B T Hennessy; S Giordano; K Broglio; Z Duan; J Trent; T A Buchholz; G Babiera; G N Hortobagyi; V Valero
Journal:  Ann Oncol       Date:  2006-02-09       Impact factor: 32.976

8.  Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis.

Authors:  M J Gaffey; S E Mills; H F Frierson; R J Zarbo; J C Boyd; J F Simpson; L M Weiss
Journal:  Mod Pathol       Date:  1995-01       Impact factor: 7.842

9.  Typical medullary carcinoma of the breast: a clinical and pathological analysis of 52 cases.

Authors:  M Reinfuss; A Stelmach; J Mitus; J Rys; K Duda
Journal:  J Surg Oncol       Date:  1995-10       Impact factor: 3.454

10.  Clinical characteristics of different histologic types of breast cancer.

Authors:  C I Li; D J Uribe; J R Daling
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

View more
  1 in total

1.  Downregulation of TBC1 Domain Family Member 24 (BC1D24) Inhibits Breast Carcinoma Growth via IGF1R/PI3K/AKT Pathway.

Authors:  Xiusheng Qu; Bin Zhao; Min Hu; Zhiwu Ji; Jian Xu; Weibin Xia; Yikun Qu
Journal:  Med Sci Monit       Date:  2018-06-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.